AstraZeneca and Seres Therapeutics Enters into Research Collaboration for 3yrs.
Shots:
- Seres to receive $20M in three equal installments and have rights for targeted microbiome therapeutics for cancer immunotherapy. AZ to get an option to negotiate rights and share the development cost
- The focus of the agreement is to develop microbiome for immuno-oncology by using Seres’ expertise in microbiome with AstraZeneca’s experience in oncology products
- Seres’ leading microbiome candidates includes SER-109 & has received FDA’s BT & OD designation. SER-287 & SER-401 is currently being evaluated in P-II b & P-I b studies respectively
Ref: Seres Therapeutics | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com